家庭COVID-19检测是否偏倚COVID-19疫苗有效性估计?
美国流感疫苗有效性网络在2022年1月至5月开展检测阴性病例对照研究,纳入2614名因急性呼吸道疾病就诊的门诊患者,询问就诊前家庭COVID-19检测情况并实验室检测SARS-CoV-2。家庭检测与当前(≤6个月)COVID-19疫苗接种、咳嗽和大学及以上学历正相关,与既往COVID-19检测阳性负相关;调整后疫苗有效性为35%(95%CI=22%,45%),加入家庭检测后为37%(95%CI=13%,46%),家庭检测者疫苗有效性为31%(95%CI=13%,46%),未检测者为43%(95%CI=24%,57%)。
要点
- 家庭COVID-19检测与当前(≤6个月)COVID-19疫苗接种独立相关(AOR=1.70;95%CI=1.19,2.42)。
- 家庭检测者疫苗有效性为31%(95%CI=13%,46%),未检测者为43%(95%CI=24%,57%)。
- 调整后模型疫苗有效性35%(95%CI=22%,45%),加入家庭检测后为37%(95%CI=13%,46%)。
核心结论
- 就诊前报告家庭COVID-19检测的患者与未使用家庭检测的患者存在差异,可能影响某些人群中COVID-19疫苗有效性的估计。
研究设计与样本
- 检测阴性病例对照研究,2022年1月至5月在美国流感疫苗有效性网络门诊患者中开展,共纳入2614名因急性呼吸道疾病就诊者,询问就诊前家庭COVID-19检测情况并实验室检测SARS-CoV-2。
主要发现
- 家庭COVID-19检测与当前(≤6个月)COVID-19疫苗接种(AOR=1.70;95%CI=1.19,2.42)、咳嗽(AOR=1.69;95%CI=1.22,2.34)和大学及以上学历(AOR=1.67;95%CI=1.37,2.03)显著正相关,与既往COVID-19检测阳性负相关。
- COVID-19疾病与咳嗽(AOR=3.07;95%CI=2.04,4.61)、接触COVID-19病例(AOR=2.41;95%CI=1.93,3.0)和家庭检测(AOR=1.87;95%CI=1.53,2.29)相关,与既往COVID-19检测阳性负相关。
- 仅当前疫苗接种与COVID-19感染的未调整模型OR为0.78(95%CI=0.66,0.92);调整种族/民族、年龄、发病至入组天数、既往COVID-19疾病和研究站点后AOR为0.65(95%CI=0.55,0.78),估计疫苗有效性为35%(95%CI=22%,45%)。
- 在调整模型中加入家庭检测后,疫苗有效性为37%(95%CI=13%,46%);家庭检测者疫苗有效性为31%(95%CI=13%,46%),未家庭检测者为43%(95%CI=24%,57%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: COVID-19 home testing became widely available in early 2021. Care seeking for acute respiratory illness and COVID-19 vaccine effectiveness estimates may be affected by home testing. METHODS: In a test-negative case-control study, between January and May 2022, U.S. Flu VE Network outpatients were asked about their home COVID-19 testing before seeking care for acute respiratory illness and were laboratory tested for SARS-CoV-2. Associations among home testing, care seeking, and COVID-19 vaccine effectiveness were assessed using multivariable logistic regression. RESULTS: Among 2,614 enrollees, home COVID-19 testing was significantly associated with current (≤6 months) COVID-19 vaccination (AOR=1.70; 95% CI=1.19, 2.42), cough (AOR=1.69; 95% CI=1.22, 2.34), and having a college degree or higher (AOR=1.67; 95% CI=1.37, 2.03) and was negatively associated with a prior positive COVID-19 test. COVID-19 illness was associated with cough (AOR=3.07; 95% CI=2.04, 4.61), contact with a COVID-19 case (AOR=2.41; 95% CI=1.93, 3.0), and home testing (AOR=1.87; 95% CI=1.53, 2.29) and was negatively associated with a prior positive COVID-19 test. In unadjusted modeling with only the association between current vaccination and COVID-19 infection, the OR was 0.78 (95% CI=0.66, 0.92). Adjusting for patient race/ethnicity, age, days from onset to enrollment, prior COVID-19 illness, and study site, the AOR was 0.65 (95% CI=0.55, 0.78). Estimated vaccine effectiveness was 35% (95% CI=22%, 45%). Adding home testing to this adjusted model, vaccine effectiveness was 37% (95% CI=13%, 46%). Among patients who home tested, vaccine effectiveness was 31% (95% CI=13%, 46%) versus 43% (95% CI=24%, 57%) among patients who did not. CONCLUSIONS: Patients reporting home testing for COVID-19 before seeking outpatient care for acute respiratory illness differed from patients not using home tests, which could affect estimates of COVID-19 vaccine effectiveness in some populations.
引用
- Nowalk MP, Balasubramani GK, D'Agostino H, et al. Does Home COVID-19 Testing Bias COVID-19 Vaccine Effectiveness Estimates? Am J Prev Med. 2025. PMID: 40945668. doi:10.1016/j.amepre.2025.108096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。